TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp‐ and BCRP‐mediated efflux

The overexpression of efflux transporters, especially P‐glycoprotein (Pgp, MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2), represents an important mechanism of multidrug resistance (MDR). Tyrosine kinase inhibitors (TKIs), a novel group of target‐specific anticancer drugs, have recently been found to interact with Pgp and BCRP and to serve as both substrates and inhibitors. Considering their dual role, we anticipate that combination TKI therapy may represent a promising strategy to reverse efflux transporter mediated TKI resistance. Presently, investigations on these interactions are very limited. To fill the literature gap, dasatinib was used as the model drug and the effects of various TKIs on Pgp‐ and BCRP‐ mediated dasatinib efflux were evaluated. Cell uptake studies were performed using LLC‐PK1 and MDCK‐II cells along with their subclones that were transfected with human Pgp and BCRP, respectively. Among the 14 TKIs screened, nine TKIs greatly inhibited Pgp‐mediated dasatinib efflux at 50 μm. Further concentration dependent studies showed that imatinib, nilotinib and pazopanib were potent Pgp inhibitors with IC50 values of 2.42, 6.11 and 8.06 μm, respectively. Additionally, 50 μm of five TKIs greatly increased dasatinib accumulation through BCRP inhibition. Concentration dependent studies revealed that imatinib, erlotinib, nilotinib, axitinib and pazopanib were potent BCRP inhibitors with IC50 values of 0.94, 2.23, 2.50, 6.89 and 10.4 μm, respectively. Our findings point to potential combinations of TKIs that could enhance intracellular concentrations of the targeted TKI, overcome MDR and improve TKI efficacy. Further in vivo studies are warranted to confirm the efflux transporter‐mediated TKI–TKI interaction. Copyright © 2016 John Wiley & Sons, Ltd.

[1]  Liwu Fu,et al.  Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. , 2013, Cancer letters.

[2]  Sagar Agarwal,et al.  Brain Distribution and Bioavailability of Elacridar after Different Routes of Administration in the Mouse , 2012, Drug Metabolism and Disposition.

[3]  S. Giordano,et al.  ReviewMolecular mechanisms of acquired resistance to tyrosine kinase targeted therapy , 2015 .

[4]  Fabian Müller,et al.  Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects , 2013, Pharmacological Reviews.

[5]  P. Houghton,et al.  Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Stewart,et al.  Role of ATP-Binding Cassette and Solute Carrier Transporters in Erlotinib CNS Penetration and Intracellular Accumulation , 2010, Clinical Cancer Research.

[7]  T. Fojo,et al.  ABC Transporters: Involvement in Multidrug Resistance and Drug Disposition , 2014 .

[8]  Zhe-Sheng Chen,et al.  Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. , 2009, Biochemical pharmacology.

[9]  T. Merchant,et al.  Phase I and Pharmacokinetic Studies of Erlotinib Administered Concurrently with Radiotherapy for Children, Adolescents, and Young Adults with High-Grade Glioma , 2009, Clinical Cancer Research.

[10]  K. Shannon Resistance in the land of molecular cancer therapeutics. , 2002, Cancer cell.

[11]  Jos H. Beijnen,et al.  Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment , 2009, Clinical Cancer Research.

[12]  Pramodita Sharma 2012 , 2013, Les 25 ans de l’OMC: Une rétrospective en photos.

[13]  J. Melo,et al.  Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications , 2008, Clinical Cancer Research.

[14]  S. Ambudkar,et al.  Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[15]  L. Fu,et al.  Interaction of tyrosine kinase inhibitors with the MDR- related ABC transporter proteins. , 2010, Current drug metabolism.

[16]  B. Qin,et al.  Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib. , 2012, International journal of pharmaceutics.

[17]  Wolfgang Löscher,et al.  Differences in the expression of endogenous efflux transporters in MDR1‐transfected versus wildtype cell lines affect P‐glycoprotein mediated drug transport , 2010, British journal of pharmacology.

[18]  C. Waters,et al.  Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas. , 2010, Cancer research.

[19]  S. Baker,et al.  Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide , 2013, Clinical Cancer Research.

[20]  J. Blay,et al.  A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors , 2009, Clinical Cancer Research.

[21]  M. Harrison Pharmacotherapy Options in Advanced Renal Cell Carcinoma: What Role for Pazopanib? , 2011, Clinical Medicine Insights. Oncology.

[22]  J. Markowitz,et al.  Enzyme- and transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors. , 2014, Journal of pharmaceutical sciences.

[23]  Michael O'Connor,et al.  A novel application of t-statistics to objectively assess the quality of IC50 fits for P-glycoprotein and other transporters , 2014, Pharmacology research & perspectives.

[24]  Ian F Tannock,et al.  The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors , 2009, BMC Cancer.

[25]  L. Fu,et al.  Mechanisms of acquired resistance to tyrosine kinase inhibitors , 2011 .

[26]  M. Rudek,et al.  Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib , 2015, Cancer Chemotherapy and Pharmacology.

[27]  P. Lakshmi,et al.  Overview of P-glycoprotein inhibitors: a rational outlook , 2012 .

[28]  A. Mitra,et al.  Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors , 2014, Drug metabolism and drug interactions.

[29]  Caroline A. Lee,et al.  In Vitro Characterization of Axitinib Interactions with Human Efflux and Hepatic Uptake Transporters: Implications for Disposition and Drug Interactions , 2013, Drug Metabolism and Disposition.

[30]  A. Ardizzoni,et al.  Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines , 2015, PloS one.

[31]  M. Pirmohamed,et al.  Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. , 2008, Blood.

[32]  J. Markowitz,et al.  ABC Transporters in Multi-Drug Resistance and ADME-Tox of Small Molecule Tyrosine Kinase Inhibitors , 2014, Pharmaceutical Research.

[33]  Peter Lloyd,et al.  Clinical Pharmacokinetics of Imatinib , 2005, Clinical pharmacokinetics.

[34]  K. Giacomini,et al.  Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins , 2011, Molecular Cancer Therapeutics.

[35]  P. Manley,et al.  Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs. , 2007, Blood.

[36]  G. Szakács,et al.  Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti‐cancer effects and pharmacological properties , 2009, British journal of pharmacology.

[37]  Balázs Sarkadi,et al.  The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). , 2008, Drug discovery today.

[38]  D. Murry,et al.  A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans , 2015, The AAPS Journal.

[39]  U. Fuhr,et al.  Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors , 2011, Clinical pharmacokinetics.

[40]  S. Bates,et al.  The challenge of exploiting ABCG2 in the clinic. , 2011, Current pharmaceutical biotechnology.

[41]  M. He,et al.  Reversing multidrug resistance by tyrosine kinase inhibitors , 2012, Chinese journal of cancer.

[42]  R. Perez-soler,et al.  Tyrosine kinase inhibitors: A clinical perspective , 2002, Current oncology reports.

[43]  P. le Coutre,et al.  Emerging Role of Tyrosine Kinases as Drugable Targets in Cancer , 2015, Biomarker insights.

[44]  Brett Fleisher,et al.  Ingredients in fruit juices interact with dasatinib through inhibition of BCRP: a new mechanism of beverage-drug interaction. , 2015, Journal of pharmaceutical sciences.

[45]  Y. Sugimoto,et al.  Gefitinib reverses breast cancer resistance protein-mediated drug resistance. , 2004, Molecular cancer therapeutics.

[46]  T. Friedberg,et al.  Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man. , 2002, Biochemical pharmacology.